Drug
IMM2510
IMM2510 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Not yet recruiting2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting125%
unknown125%
not_yet_recruiting250%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_1
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787
recruitingphase_1
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836
not_yet_recruitingphase_2
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
NCT06746870
unknownphase_1
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
NCT05972460
Clinical Trials (4)
Showing 4 of 4 trials
NCT07170787Phase 1
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836Phase 1
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06746870Phase 2
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
NCT05972460Phase 1
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4